Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

The global premature ejaculation (PE) market is expected to cross $1.9 billion, growing impressively at a CAGR of 8.9% during the period 2016-2022

ReportBuyer
Posted on: 28 Nov 17
The global premature ejaculation (PE) market is expected to cross $1.9 billion, growing impressively at a CAGR of 8.9% during the period 2016-2022

PR Newswire

LONDON, Nov. 28, 2017

LONDON, Nov. 28, 2017 /PRNewswire/ -- Innovus Pharma, Plethora Solutions, Absorption Pharmaceuticals and Allergan are the leading companies dominating the premature ejaculation market. The global premature ejaculation (PE) market is expected to cross $1.9 billion, growing impressively at a CAGR of 8.9% during the period 2016?2022. A high burden of PE prevalence and associated chronic condition, which can, in turn, poses as a high-risk factor for the occurrence of this disease is the key market driver for the premature ejaculation market in both developing and developed countries. Regionally, the US is the main contributor to the global PE market. Despite the absence of PE drug in the US, the market in North America retains dominant share because of wide accessibility to PE off-labels and OTC drugs. In terms of route of administration, the oral drugs segment contributes a dominant share of nearly three-fourths of the global market.



Download the full report: https://www.reportbuyer.com/product/5219025



Report Timeline
Base Year: 2016
Forecast Year: 2017?2022

Major vendors profiled in the report are as following:
Innovus Pharma
Plethora Solutions
Absorption Pharmaceuticals
Allergan

Other prominent vendors include Menarini, GlaxoSmithKline, Ixchelsis, Dong-A Pharmaceutical, NeuroHealing Pharmaceuticals.

Scope of the Report
The report considers the present scenario of the global premature ejaculation market and its in-depth analysis for the period 2017–2022. It includes a detailed study of growth drivers, trends, and restraints. The report also profiles the leading vendors in the market and other key vendors.

The report provides the analysis of key segments of the market by route administration, mechanism of action, geography, and vendors. It provides a detailed analysis of revenue from various segments:

Route Administration
Topical therapies
Oral therapy

Mechanism of Action
SSRI
PDE5 inhibitors
Ester/Amide anesthetics

Geography
APAC
Europe
Latin America
MEA
North America

Major trends, drivers, and restraints for each geography are included in the report.
Premature ejaculation (PE) is a male sexual dysfunction, which is characterized by the inability to delay ejaculation for more than one minute after penetration or sexual stimulation. The condition is associated with uncontrolled ejaculation either before or shortly after sexual penetration, or with minimal sexual stimulation.

The global premature ejaculation market is expected to cross $1.9 billion, growing impressively at a CAGR of 8.9% during the period 2016?2022. Increasing disease awareness, growing patient willingness to seek pharmaceutical therapy assistance for disease management and increasing presence of favorable guidelines, which recommended the use of drugs as first-line therapy for treatment of PE, will augment market prospects during the forecast period.

The report provides a holistic view of the global premature ejaculation market, the companies involved in the market, and the factors driving its growth. The report also provides information about the latest trends that are likely to become strong market driving forces over the next five years. This report also provides the Porter's Five Forces analysis along with a description of each force and its impact on the market. Further, the report also provides complete value chain analysis of the global market.

Premature Ejaculation Market Dynamics
Emphasis on clinical progress of love hormone receptor antagonists to drive the market growth

Increase in prevalence of chronic diseases, low-effectiveness of non-pharmacological treatment, and a wide accessibility to premature ejaculation OTC drugs and generic off-label drugs are the prime factors that are going to escalate the market growth during the forecast period. Furthermore, pharmaceutical advances in PE drug formulation technology, emphasis on clinical progress of love hormone receptor antagonists, and launch of premature ejaculation treatment awareness campaigns are the latest trends that are likely to positively impact the market. The report also provides the key restraints of the market.

Premature Ejaculation Market: Segmental Overview
The amide anesthetics segment is the fast-growing segment in terms of mechanism of action.

The oral drug segment to remain the dominant market in terms of route of administration. The topical PE drugs market is expected to witness growth at a higher pace than the oral PE drugs market. However, the oral PE drugs market is likely to retain its market share until the end of the forecast period.

In terms of mechanism of action (MOA), the global PE market broad segments include SSRIs, PDE5 inhibitors, and amide anesthetics. In 2016, the SSRIs segment dominated the market. This segment is anticipated to retain its dominance till the end of forecast period. The amide anesthetics segment, which occupied low share in 2016, is anticipated to witness higher growth than the other drug MOAs segment during the period 2016-2022.

Premature Ejaculation Market: Geographical Analysis
North America to remain the largest market followed by Europe

The premature ejaculation market in North America is the largest due to high prevalent PE population. The US occupies approximately 90% of the PE market in North America due to the high population density and comparably higher utilization of off-label and OTC PE products. Similarly, the UK, Germany, France, Spain, and Italy are the leading markets for PE therapies in the European region. The market in APAC is likely to witness the highest growth rate during the forecast period. A significant increase in PE incidence due to growing burden of chronic conditions, which, in turn, is associated with the high risk of PE occurrence is expected to boost the market growth in this region. The prevalence of PE in the Middle East countries and Latin America is estimated to be lowest than other regions. The market, however, is anticipated to witness a moderate growth rate in these regions.

Download the full report: https://www.reportbuyer.com/product/5219025

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com   
Email: query@reportbuyer.com  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com  

View original content:http://www.prnewswire.com/news-releases/the-global-premature-ejaculation-pe-market-is-expected-to-cross-19-billion-growing-impressively-at-a-cagr-of-89-during-the-period-2016-2022-300562658.html

SOURCE ReportBuyer

PR Newswire
www.prnewswire.com

Last updated on: 28/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.